Last checked at 
April 15 (Reuters) - The U.S. Food and Drug Administrationapproved GlaxoSmithKline Plc's Tanzeum injection fortreating adults with type 2 diabetes, in combination with dietand exercise.
Tanzeum will carry a warning on its label that tumors of thethyroid gland were observed in rodent studies with some drugsbelonging to the same class. However, it is unknown whetherTanzeum causes thyroid C-cell tumors, the FDA said on itswebsite. (http://link.reuters.com/jyp58v)
The once-weekly drug, generically known as albiglutide, wasapproved last month in Europe, where it will be marketed asEperzan.
Tanzeum belongs to the same class of injectable GLP-1 drugsas Victoza from Novo Nordisk and Byetta and Bydureonfrom AstraZeneca. (Reporting by Esha Dey in Bangalore; Editing by SaumyadebChakrabarty)
